Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Common Equity (2018 - 2025)

Historic Common Equity for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $1.6 billion.

  • Revolution Medicines' Common Equity rose 195.36% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 195.36%. This contributed to the annual value of $2.3 billion for FY2024, which is 2403.96% up from last year.
  • Revolution Medicines' Common Equity amounted to $1.6 billion in Q3 2025, which was up 195.36% from $1.9 billion recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Common Equity registered a high of $2.3 billion during Q4 2024, and its lowest value of $498.8 million during Q2 2022.
  • In the last 5 years, Revolution Medicines' Common Equity had a median value of $930.8 million in 2023 and averaged $1.2 billion.
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 2717.71% in 2022, then skyrocketed by 16652.45% in 2023.
  • Over the past 5 years, Revolution Medicines' Common Equity (Quarter) stood at $602.6 million in 2021, then grew by 13.71% to $685.2 million in 2022, then soared by 166.52% to $1.8 billion in 2023, then increased by 24.04% to $2.3 billion in 2024, then decreased by 29.5% to $1.6 billion in 2025.
  • Its Common Equity was $1.6 billion in Q3 2025, compared to $1.9 billion in Q2 2025 and $2.1 billion in Q1 2025.